Company Overview More
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
CEO: Coric M.D., Vladimir
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

BHVN Biohaven Pharmaceutical
140.600-0.400-0.28%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
6.4% 602.48M 2.61% 364.59M 2.61% 364.59M -4.72% 520.44M
-Cash and cash equivalents
-63.62% 169.07M 30.11% 171.95M 30.11% 171.95M 58.56% 501.41M
-Short-term investments
326.81% 433.41M -13.68% 192.65M -13.68% 192.65M -91.73% 19.03M
Receivables
109.44% 328.34M 156.65% 308.27M 156.65% 308.27M 218.09% 252.95M
-Accounts receivable
109.44% 328.34M 156.65% 308.27M 156.65% 308.27M 218.09% 252.95M
Inventory
56.49% 91.28M 103.75% 80.61M 103.75% 80.61M 271.88% 74.86M
Prepaid assets
-12.11% 104.89M 0.5% 88.84M 0.5% 88.84M -1.15% 61.7M
Other current assets
-- 44.1M -- 33.95M -- 33.95M -- 34.43M
Total current assets
30.02% 1.17B 45.22% 876.25M 45.22% 876.25M 33.33% 944.38M
Non current assets
Net PPE
29.1% 14.53M 57.28% 14.69M 57.28% 14.69M 18.26% 10.41M
-Gross PPE
-- -- 68.52% 19.3M -- -- -- --
-Accumulated depreciation
-- -- -118.16% -4.61M -- -- -- --
Goodwill and other intangible assets
-3.98% 55.91M 44.39% 56.44M 44.39% 56.44M 43.1% 56.97M
Investments and advances
-- -- -- 0 -- 0 -- 0
Other non current assets
294.76% 130.19M 282.24% 129.83M 282.24% 129.83M 413.69% 119.44M
Total non current assets
95.81% 200.63M 140.47% 200.96M 140.47% 200.96M 153.38% 186.81M
Total assets
36.74% 1.37B 56.81% 1.08B 56.81% 1.08B 44.65% 1.13B
Liabilities
Current liabilities
Payables
-12.96% 56.2M 6.62% 51.68M 6.62% 51.68M 12.42% 49.44M
-accounts payable
-12.96% 56.2M 6.62% 51.68M 6.62% 51.68M 12.42% 49.44M
Current accrued expenses
75.12% 422.05M 178.66% 379.91M 153.35% 420.02M 198.82% 318.04M
Other current liabilities
0% 62.5M 0% 62.5M 0% 62.5M 33.33% 62.5M
Current liabilities
45.56% 576.11M 93.02% 534.2M 93.02% 534.2M 112.91% 462.28M
Non current liabilities
Long term debt and capital lease obligation
134.2% 634.11M 134.32% 626.72M 134.32% 626.72M 134.45% 619.27M
-Long term debt
134.2% 634.11M 134.32% 626.72M 134.32% 626.72M 134.45% 619.27M
Derivative product liabilities
-36.67% 9.12M -7.61% 13.11M -7.61% 13.11M 675.77% 15.05M
Preferred securities outside stock equity
33.47% 162.99M 39.56% 155.74M 39.56% 155.74M 20.83% 144.33M
Other non current liabilities
8.98% 455.8M 23.28% 430.45M 23.28% 430.45M 26.5% 421.48M
Total non current liabilities
52.87% 1.26B 65.14% 1.23B 65.14% 1.23B 66.98% 1.2B
Total liabilities
50.5% 1.84B 72.71% 1.76B 72.71% 1.76B 77.64% 1.66B
Shareholders'equity
Share capital
31.71% 2.11B 34.19% 1.68B -- -- 35.51% 1.63B
-common stock
31.71% 2.11B 34.19% 1.68B -- -- 35.51% 1.63B
Retained earnings
-34.83% -2.7B -48.68% -2.59B -- -- -56.86% -2.39B
Paid-in capital
4.73% 129.58M 71.48% 169.66M -- -- 59.6% 165.05M
Gains losses not affecting retained earnings
-686.31% -2.4M -123.25% -73K -- -- -67.33% 82K
Total stockholders'equity
-67.51% -462.29M -89.4% -739.38M -89.4% -739.38M -176.85% -587.98M
Noncontrolling interests
-107.14% -4.13M -3.11% 56.37M -3.11% 56.37M -3.06% 56.77M
Total equity
-113.8% -466.41M -105.61% -683.01M -105.61% -683.01M -245.35% -531.21M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%